The clinical value of magnetic resonance imaging grading for prostate cancer diagnosis in patients with prostate-specific antigen levels less than 20 μg/L
10.3760/cma.j.issn.0254-9026.2013.05.022
- VernacularTitle:磁共振在前列腺特异性抗原低于20 μg/L患者中诊断前列腺癌的影像分级研究
- Author:
Xuan WANG
;
Ming LIU
;
Min CHEN
;
Chunmei LI
;
Ben WAN
;
Dong WEI
;
Jianye WANG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Magnetic resonance imaging;
Early detection of cancer
- From:
Chinese Journal of Geriatrics
2013;(5):532-535
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of image gradings of T2 weighted imaging (T2WI) and diffusion weighted imaging (DWI) for prostate cancer diagnosis in patients with prostate specific antigen (PSA) less than 20 μg/L.Methods A total of 133 patients with PSA＜20 μg/L who received prostate biopsies in our hospital from December 2011 to January 2013 were recruited.The prostate was divided into six regions in MRI images.T2WI and DWI image gradings on each region in peripheral zone were evaluated with reference to histopathological evaluation of prostate biopsies.The significance of grading system for the diagnosis of prostate cancer in the two scanning methods alone or in combination were compared.Results 60 patients were diagnosed as prostate cancer.The positive biopsy rates were 2.8％,13.5％,20.4％,34.6％,52.6％ and 88.9％,respectively in grade 0-5 based on T2WI imaging grading.The positive biopsy rates were 11.1％,16.1％,48.5％,71.0％ and 86.1％,respectively in grade 1-5 based on T2WI+ DWI imaging grading.The positive biopsy rate was significantly increased with the increments of pre-established T2WI and T2WI+DWI image gradings (Z=-9.8552,-13.4148,both P＜0.0001).Receiver operating characteristic analysis showed that the diagnostic capability was better in T2WI combined with DWI than in T2W1 alone in prostate cancer detection (AUC:0.743 vs.0.715,P=0.0072).Conclusions T2WI image grading can predict the risk of prostate cancer in patients with PSA＜20 μg/L,and DWI can enhance the ability to predict prostate cancer.
